桃仁-红花药对对动静力失衡性大鼠椎间盘软骨终板退变的影响  

Effects of Taoren-Honghua drug pair on degeneration of cervical disc cartilage endplate in rat model of dynamic and static forces imbalance

作　　者：王艺儒 唐德志 梁倩倩[2,3] 徐浩 赵永见[2,3] 郑为超 

机构地区：[1]安徽理工大学医学院,安徽淮南232001 [2]筋骨理论与治法教育部重点实验室,上海200032 [3]上海中医药大学脊柱病研究所,上海200032

出　　处：《中国药理学通报》2018年第2期279-283,共5页Chinese Pharmacological Bulletin

基　　金：国家自然科学基金资助项目(No 81273777)

摘　　要：目的探讨桃仁-红花药对对大鼠颈椎间盘软骨终板退变的影响。方法选取清洁级健康Wistar大鼠50只,♂,随机分为对照组、模型组、假手术组、美洛昔康组、桃仁-红花药对组,每组10只。其中模型组、美洛昔康组、桃仁-红花药对组通过手术方法建立动静力失衡性大鼠椎间盘退变模型,假手术组切开皮肤后不做进一步操作。造模12周后,对照组、模型组、假手术组每日给予生理盐水灌胃,美洛昔康组、桃仁-红花药对组每日分别给予等量美洛昔康悬浊液、桃仁-红花煎剂灌胃,连续给药30 d后处死全部大鼠,完整取出C_(4/5)、C_(6/7)椎间盘。C_(4/5)椎间盘固定、切片,ABOG染色法观察椎间盘组织形态学变化;免疫组化法检测Ⅱ型胶原(type Ⅱ collagen,Col Ⅱ)、X型胶原(type X collagen,Col X)蛋白的表达情况;C_(6/7)椎间盘提取总mRNA,实时定量PCR检测Col Ⅱ、Col X基因的表达情况。结果与模型组比较,桃仁-红花药对组上调软骨终板细胞Col Ⅱ的mRNA及蛋白表达,下调软骨终板细胞Col X的mRNA及蛋白表达,差异有统计学意义(P<0.01)。结论桃仁-红花药对可以抑制动静力失衡性大鼠椎间盘退变中的软骨终板退变,进而延缓椎间盘退变。Aim To investigate the effect of TaorenHonghua drug pair on intervertebral disc degeneration( IVDD) in rats. Methods Fifty healthy Wistar rats were randomly divided into control group, model group,sham group,meloxicam group and Taoren-Honghua drug pair group,with 10 rats in each group. We established dynamic and static forces imbalance of cervical disc degeneration model or sham surgery in rats.12 weeks later,rats were intragastrically administered with meloxicam,Taoren-Honghua drug pair or saline for 30 days. C_(4/5) and C_(6/7) discs were harvested from rats. ABOG staining was used for observation of intervertebral disc morphology,real time PCR for mRNA expressions of type Ⅱ collagen( Col Ⅱ) and type Ⅹcollagen( Col X),and immunohistochemical staining for Col Ⅱ and Col X. Results Compared with model group,Col Ⅱ expression increased,while Col X expression decreased in chondrocyte of intervertebral disc in Taoren-Honghua-treated group( P < 0. 01). Conclusion Taoren-Honghua drug pair could delay the degeneration of cartilage endplate in rat intervertebral disc.

关 键 词：药对 椎间盘 退变 软骨终板 Ⅱ型胶原 Ⅹ型胶原 

分 类 号：R-332[医药卫生] R289